NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal
This article was originally published in The Tan Sheet
Executive Summary
Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow by aiming straight for the OTC market with the help of GlaxoSmithKline
You may also be interested in...
In Brief
Prestige Brands gains from acquisitions
GSK Expands Consumer Business With Acquisition Of OTC Cold Sore Products
GlaxoSmithKline further expands its rapidly growing consumer health care business by acquiring exclusive marketing rights to two cold sore treatments in a week, just months after announcing a third deal in the category
GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says